Adams GP, Weiner LM. Monoclonal antibody therapy of cancer. Nat Biotechnol. 2005;23(9):1147–57.

Article  CAS  PubMed  Google Scholar 

Rajasekaran N, Chester C, Yonezawa A, Zhao X, Kohrt HE. Enhancement of antibody-dependent cell mediated cytotoxicity: a new era in cancer treatment. Immunotargets Ther. 2015;4:91–100.

PubMed  PubMed Central  Google Scholar 

Houot R, Kohrt H, Levy R. Boosting antibody-dependant cellular cytotoxicity against tumor cells with a CD137 stimulatory antibody. Oncoimmunology. 2012;1(6):957–8.

Article  PubMed  PubMed Central  Google Scholar 

Alderson KL, Sondel PM. Clinical cancer therapy by NK cells via antibody-dependent cell-mediated cytotoxicity. J Biomed Biotechnol. 2011;2011: 379123.

Article  PubMed  PubMed Central  Google Scholar 

Ravetch JV, Bolland S. IgG Fc receptors. Annu Rev Immunol. 2001;19:275–90.

Article  CAS  PubMed  Google Scholar 

Manches O, Lui G, Chaperot L, Gressin R, Molens JP, Jacob MC, et al. In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas. Blood. 2003;101(3):949–54.

Article  CAS  PubMed  Google Scholar 

Reff ME, Carner K, Chambers KS, Chinn PC, Leonard JE, Raab R, et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood. 1994;83(2):435–45.

Article  CAS  PubMed  Google Scholar 

Kawasaki N, Yamashita-Kashima Y, Fujimura T, Yoshiura S, Harada N, Kondoh O, et al. Resistance to obinutuzumab-induced antibody-dependent cellular cytotoxicity caused by abnormal Fas signaling is overcome by combination therapies. Mol Biol Rep. 2022;49(6):4421–33.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kurai J, Chikumi H, Hashimoto K, Yamaguchi K, Yamasaki A, Sako T, et al. Antibody-dependent cellular cytotoxicity mediated by cetuximab against lung cancer cell lines. Clin Cancer Res. 2007;13(5):1552–61.

Article  CAS  PubMed  Google Scholar 

Pahl JH, Ruslan SE, Buddingh EP, Santos SJ, Szuhai K, Serra M, et al. Anti-EGFR antibody cetuximab enhances the cytolytic activity of natural killer cells toward osteosarcoma. Clin Cancer Res. 2012;18(2):432–41.

Article  CAS  PubMed  Google Scholar 

Kimura H, Sakai K, Arao T, Shimoyama T, Tamura T, Nishio K. Antibody-dependent cellular cytotoxicity of cetuximab against tumor cells with wild-type or mutant epidermal growth factor receptor. Cancer Sci. 2007;98(8):1275–80.

Article  CAS  PubMed  Google Scholar 

Kawaguchi Y, Kono K, Mimura K, Sugai H, Akaike H, Fujii H. Cetuximab induce antibody-dependent cellular cytotoxicity against EGFR-expressing esophageal squamous cell carcinoma. Int J Cancer. 2007;120(4):781–7.

Article  CAS  PubMed  Google Scholar 

Hara M, Nakanishi H, Tsujimura K, Matsui M, Yatabe Y, Manabe T, et al. Interleukin-2 potentiation of cetuximab antitumor activity for epidermal growth factor receptor-overexpressing gastric cancer xenografts through antibody-dependent cellular cytotoxicity. Cancer Sci. 2008;99(7):1471–8.

Article  CAS  PubMed  Google Scholar 

• Chew HY, De Lima PO, Gonzalez Cruz JL, Banushi B, Echejoh G, Hu L, et al. Endocytosis inhibition in humans to improve responses to ADCC-mediating antibodies. Cell. 2020;180(5):895-914.e27. This paper highlights the significant role of ADCC in the function of both cetuximab and trastuzumab.

Article  CAS  PubMed  Google Scholar 

Srivastava RM, Lee SC, Andrade Filho PA, Lord CA, Jie H-B, Davidson HC, et al. Cetuximab-activated natural killer and dendritic cells collaborate to trigger tumor antigen–specific T-cell immunity in head and neck cancer patients. Clin Cancer Res. 2013;19(7):1858–72.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med. 2000;6(4):443–6.

Article  CAS  PubMed  Google Scholar 

Moretta A, Bottino C, Vitale M, Pende D, Cantoni C, Mingari MC, et al. Activating receptors and coreceptors involved in human natural killer cell-mediated cytolysis. Annu Rev Immunol. 2001;19:197–223.

Article  CAS  PubMed  Google Scholar 

Muntasell A, Cabo M, Servitja S, Tusquets I, Martínez-García M, Rovira A, et al. Interplay between natural killer cells and anti-HER2 antibodies: perspectives for breast cancer immunotherapy. Front Immunol. 2017;8:1544.

Article  PubMed  PubMed Central  Google Scholar 

Wang W, Erbe AK, Hank JA, Morris ZS, Sondel PM. NK cell-mediated antibody-dependent cellular cytotoxicity in cancer immunotherapy. Front Immunol. 2015;6:368.

Article  PubMed  PubMed Central  Google Scholar 

Imai K, Takaoka A. Comparing antibody and small-molecule therapies for cancer. Nat Rev Cancer. 2006;6(9):714–27.

Article  CAS  PubMed  Google Scholar 

Online eCT. Cancer Institute NSW 2023 [Available from: https://www.eviq.org.au/. Accessed 30 Aug 2023.

Online eCT. Breast neoadjuvant DOCEtaxel, pERTUZumab and trastuzumab 2021 [Available from: https://www.eviq.org.au/medical-oncology/breast/adjuvant-neoadjuvant/1969-breast-neoadjuvant-docetaxel-pertuzumab-and. Accessed 30 Aug 2023.

Online ECT. Breast metastatic trastuzumab deruxtecan 2022 [Available from: https://www.eviq.org.au/medical-oncology/breast/metastatic/4150-breast-metastatic-trastuzumab-deruxtecan.

Rugo HS, Bianchini G, Cortes J, Henning JW, Untch M. Optimizing treatment management of trastuzumab deruxtecan in clinical practice of breast cancer. ESMO Open. 2022;7(4): 100553.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Goto E, Hata T, Nishihara M, Neo M, Iwamoto M, Kimura K, et al. Preventive effect of dexamethasone premedication on the development of infusion-related reaction in breast cancer patients receiving trastuzumab. Br J Clin Pharmacol. 2023;89(7):2102–12.

Article  CAS  PubMed  Google Scholar 

Touma W, Koro SS, Ley J, Wildes TM, Michel L, Tao Y, et al. Risk factors for and pre-medications to prevent cetuximab-induced infusion reactions in patients with squamous cell carcinoma of the head and neck. Oral Oncol. 2014;50(9):895–900.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Online eCT. Head and neck squamous cell carcinoma locally advanced definitive cetuximab chemoradiation 2019.

Association TG. AUSTRALIAN PRODUCT INFORMATION – ERBITUX® (cetuximab (rmc)) solution for injection (intravenous infusion) 2019 [updated 24 October 2019. Available from: https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2010-PI-01421-3. Accessed 30 Aug 2023.

Association TG. ERBITUX® cetuximab (rmc) CONSUMER MEDICINE INFORMATION 2019 [updated October 2019. Available from: https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2010-CMI-01424-3. Accessed 30 Aug 2023.

Izzedine H, Mathian A, Amoura Z, Ng JH, Jhaveri KD. Anticancer drug-induced capillary leak syndrome. Kidney Int Rep. 2022;7(5):945–53.

Article  PubMed  PubMed Central  Google Scholar 

• Cooper JA Jr, Daniels CA, Trofatter EF Jr. The effect of prednisolone on antibody-dependent cell-mediated cytotoxicity and the growth of type I herpes simplex virus in human cells. Invest Ophthalmol Vis Sci. 1978;17(4):381–5. To the authors’ knowledge, this is the first article that linked corticosteroids with ADCC inhibition.

CAS  PubMed  Google Scholar 

Nair MP, Schwartz SA. Immunomodulatory effects of corticosteroids on natural killer and antibody-dependent cellular cytotoxic activities of human lymphocytes. J Immunol. 1984;132(6):2876–82.

Article  CAS  PubMed  Google Scholar 

•• Kumai T, Oikawa K, Aoki N, Kimura S, Harabuchi Y, Kobayashi H. Assessment of the change in cetuximab-induced antibody-dependent cellular cytotoxicity activity of natural killer cells by steroid. Head Neck. 2016;38(3):410–6. Demonstrated inhibition of cetuximab-induced ADCC activity in head and neck squamous cell carcinoma and colon cancer.

Article  PubMed  Google Scholar 

•• Sumikawa T, Shigeoka Y, Igishi T, Suyama H, Yamasaki A, Hashimoto K, et al. Dexamethasone interferes with trastuzumab-induced cell growth inhibition through restoration of AKT activity in BT-474 breast cancer cells. Int J Oncol. 2008;32(3):683–8. Preclinical models demonstrating that dexamethasone interferes with trastuzumab-induced cell growth inhibition.

CAS  PubMed  Google Scholar 

Rose AL, Smith BE, Maloney DG. Glucocorticoids and rituximab in vitro: synergistic direct antiproliferative and apoptotic effects. Blood. 2002;100(5):1765–73.

Article  CAS  PubMed  Google Scholar 

Dworzak MN, Schumich A, Printz D, Pötschger U, Husak Z, Attarbaschi A, et al. CD20 up-regulation in pediatric B-cell precursor acute lymphoblastic leukemia during induction treatment: setting the stage for anti-CD20 directed immunotherapy. Blood. 2008;112(10):3982–8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bloomfield CD, Smith KA, Peterson BA, Hildebrandt L, Zaleskas J, Gajl-Peczalska KJ, et al. In-vitro glucocorticoid studies for predicting response to glucocorticoid therapy in adults with malignant lymphoma. Lancet. 1980;1(8175):952–6.

Article  CAS  PubMed  Google Scholar